Remove tag market-access
article thumbnail

Generative AI with Google Lens to detect counterfeits in pharma

Express Pharma

Generative AI will be used to create unique invisible image tags for each product (like UID). This can be done by training the AI on a dataset of existing batch numbers, allowing it to generate new, unique invisible image tags on brand logo / brand name that cannot be replicated by counterfeiters 2.

article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 Pause in UK access.

119
119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Benefits of blockchain in limiting counterfeit drug distribution

European Pharmaceutical Review

While the counterfeit market is estimated to be a market of over $200 billion and despite its benefits, blockchain technology has not been fully implemented in the pharmaceutical supply chain, according to the paper. Blockchain offers the possibility of non-modifiable data uploading with traceability and low-cost data storage.

90
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Go-to-market strategies. The challenge of providing adequate access to the peripheral EU markets is quite evident. Efforts have been made to change this.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s

105
105
article thumbnail

Biotech titans Bengaluru and Hyderabad fortify India’s dominance

Express Pharma

Bengaluru’s social infrastructure, characterised by top-tier educational institutions like the Indian Institute of Science, facilitates access to a highly skilled talent pool and an organically growing innovation system (4). Over the time, the city has improved its infrastructure to accommodate them.

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.

Cerner 111